High Level of Serum Cripto-1 in Hepatocellular Carcinoma, Especially with Hepatitis B Virus Infection

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Sep 2

PMID 30170372

Citations 8

Authors

Yingyu Zhang

Hongqin Xu

Xiumei Chi

Yuxiang Fan

Ying Shi

Junqi Niu

Affiliations

Soon will be listed here.

Abstract

Background: Human Cripto-1 (CR-1), a member of the epidermal growth factor-Cripto-1/FRL-1/Cryptic protein family (EGF-CFC), is highly expressed in a variety of human cancers. We aimed to detect serum CR-1 level in liver diseases especially in hepatocellular carcinoma (HCC) patients.

Methods: Serum CR-1 level was Sandwich-type enzyme-linked immuno sorbent assay (ELISA) detected in 330 patients with liver diseases including HCC, cirrhosis, and chronic hepatitis and 50 volunteers without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as control.

Results: The serum CR-1 level was significantly higher in HCC patients than volunteer controls and it was also significantly higher in HBV-related HCC than HCV-related HCC. In addition, serum CR-1 level was correlated with serum alpha-feto-protein (AFP) in HBV-related HCC patients. The serum CR-1 was also higher in cirrhosis and chronic hepatitis than volunteer controls. The serum CR-1 in HBV-related cirrhosis was higher than chronic hepatitis B, but there was no significant difference between HCV-related cirrhosis and chronic hepatitis C.

Conclusions: Serum CR-1 was higher in HCC patients and might serve as a complementary biomarker to clinical diagnosis of HBV-related HCC. The high level of serum CR-1 in HBV-related liver disease might be partly attributed to HBV infection.

Citing Articles

Understanding the role of Cripto-1 in cancer progression and therapeutic strategies.

Zeng Q, Gao Y, Zhou Y Clin Transl Oncol. 2022; 25(5):1135-1144.

PMID: 36456761 DOI: 10.1007/s12094-022-03023-2.

Advanced Lab-on-Fiber Optrodes Assisted by Oriented Antibody Immobilization Strategy.

Ucci S, Spaziani S, Quero G, Vaiano P, Principe M, Micco A Biosensors (Basel). 2022; 12(11).

PMID: 36421158 PMC: 9688615. DOI: 10.3390/bios12111040.

Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis.

Karkampouna S, van der Helm D, Scarpa M, van Hoek B, Verspaget H, Goumans M Cells. 2021; 10(12).

PMID: 34943832 PMC: 8699799. DOI: 10.3390/cells10123325.

Whence CRIPTO: The Reemergence of an Oncofetal Factor in 'Wounds' That Fail to Heal.

Freeman D, Rodrigues Sousa E, Karkampouna S, Zoni E, Gray P, Salomon D Int J Mol Sci. 2021; 22(18).

PMID: 34576327 PMC: 8472190. DOI: 10.3390/ijms221810164.

Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways.

Liu Y, Li Y, Huang S, Li Y, Xia J, Jia J Aging (Albany NY). 2021; 13(17):21155-21190.

PMID: 34517344 PMC: 8457585. DOI: 10.18632/aging.203402.

References

Yoon H, Hong J, Shin W, Lee Y, Hong K, Lee J . The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma. Oral Oncol. 2011; 47(11):1023-31. DOI: 10.1016/j.oraloncology.2011.07.019. View

Xu C, Sheng Z, Hu H, Hao K, Wang Q, Yu L . Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer. Tumour Biol. 2014; 35(9):8673-8. DOI: 10.1007/s13277-014-2039-1. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

Mendez-Sanchez N, Villa A, Zamora-Valdes D, Morales-Espinosa D, Uribe M . Worldwide mortality from cirrhosis. Ann Hepatol. 2007; 6(3):194-5. View

El-Serag H, Marrero J, Rudolph L, Reddy K . Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134(6):1752-63. DOI: 10.1053/j.gastro.2008.02.090. View

Llovet J, Bruix J . Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48 Suppl 1:S20-37. DOI: 10.1016/j.jhep.2008.01.022. View

de Castro N, Rangel M, Nagaoka T, Salomon D, Bianco C . Cripto-1: an embryonic gene that promotes tumorigenesis. Future Oncol. 2010; 6(7):1127-42. DOI: 10.2217/fon.10.68. View

Wei B, Jin W, Ruan J, Xu Z, Zhou Y, Liang J . Cripto-1 expression and its prognostic value in human bladder cancer patients. Tumour Biol. 2014; 36(2):1105-13. DOI: 10.1007/s13277-014-2695-1. View

Bianco C, Rangel M, Castro N, Nagaoka T, Rollman K, Gonzales M . Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol. 2010; 177(2):532-40. PMC: 2913337. DOI: 10.2353/ajpath.2010.100102. View

10.

Kreso A, Dick J . Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14(3):275-91. DOI: 10.1016/j.stem.2014.02.006. View

11.

Noaksson K, Zoric N, Zeng X, Rao M, Hyllner J, Semb H . Monitoring differentiation of human embryonic stem cells using real-time PCR. Stem Cells. 2005; 23(10):1460-7. DOI: 10.1634/stemcells.2005-0093. View

12.

Bianco C, Castro N, Baraty C, Rollman K, Held N, Rangel M . Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. J Cell Physiol. 2012; 228(6):1174-88. PMC: 3573215. DOI: 10.1002/jcp.24271. View

13.

Seeff L, Hoofnagle J . Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006; 25(27):3771-7. DOI: 10.1038/sj.onc.1209560. View

14.

Chen Ban K, Singh H, Krishnan R, Seow H . Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. J Surg Oncol. 2004; 86(3):157-63. DOI: 10.1002/jso.20051. View

15.

Kwon O, Jung Y, Kim Y, Kim S, Kim Y, Lee J . Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol. 2010; 16(3):308-14. PMC: 3304590. DOI: 10.3350/kjhep.2010.16.3.308. View

16.

Feo F, De Miglio M, Simile M, Muroni M, Calvisi D, Frau M . Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta. 2005; 1765(2):126-47. DOI: 10.1016/j.bbcan.2005.08.007. View

17.

Zhong X, Zhang L, Jia S, Shi T, Niu Z, Du H . Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology. 2008; 52(5):560-8. DOI: 10.1111/j.1365-2559.2008.02971.x. View

18.

Taketa K . Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990; 12(6):1420-32. DOI: 10.1002/hep.1840120625. View

19.

Nagaoka T, Karasawa H, Turbyville T, Rangel M, Castro N, Gonzales M . Cripto-1 enhances the canonical Wnt/β-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors. Cell Signal. 2012; 25(1):178-89. PMC: 3508164. DOI: 10.1016/j.cellsig.2012.09.024. View

20.

Bianco C, Normanno N, Salomon D, Ciardiello F . Role of the cripto (EGF-CFC) family in embryogenesis and cancer. Growth Factors. 2004; 22(3):133-9. DOI: 10.1080/08977190410001723290. View